- RecruitingPHASE3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
This study is testing a new medicine called iptacopan for people aged 12-60 with a kidney disease called C3 Glomerulopathy (C3G). It aims to see if the medicine is safe and helps improve kidney function compared to a dummy pill.
For: C3GUnited States · Argentina · Belgium - RecruitingPHASE3
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
This study is testing a new medicine, iptacopan, for a kidney disease called IC-MPGN. It wants to see if the medicine can help improve kidney function and reduce protein in the urine, compared to a dummy medicine, in people aged 12 to 60.
For: IC-MPGNUnited States · Argentina · Brazil - Active not recruitingPHASE3
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
This study looks at the long-term safety and effects of a medicine called iptacopan for people with a rare blood condition called PNH. It's for patients who have already been taking iptacopan in other studies and found it helpful, to make sure they can continue treatment safely.
For: Paroxysmal Nocturnal HemoglobinuriaUnited States · Brazil · China - RecruitingPHASE3
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
This study is testing a new medicine called iptacopan for people aged 18-85 with a type of muscle weakness called generalized Myasthenia Gravis (gMG). It's compared to a dummy medicine to see if it's safe and helps improve symptoms while continuing usual care.
For: Generalized Myasthenia GravisUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy
This study is looking at a new medicine called IPTACOPAN for adults who have a rare kidney disease called atypical hemolytic uremic syndrome (aHUS). It wants to see if the medicine helps improve blood and kidney problems without needing other common treatments.
For: Atypical hemolytic uremic syndromeSlovenia · Slovakia · Czechia - RecruitingPHASE3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
This study looks at switching from current aHUS treatment (anti-C5 antibodies) to a new treatment called iptacopan. Researchers want to see if iptacopan is safe and effective for adults with aHUS who are already doing well on their current medication.
For: Atypical Hemolytic Uremic SyndromeChina · France · Germany - Active not recruitingPHASE2
Iptacopan in Patients With ANCA Associated Vasculitis
This study is looking at a new medicine called iptacopan for people with a rare condition called ANCA-associated vasculitis. It aims to see if iptacopan, when given with standard treatment, can help people get better and stay better, and if it's safe to use.
For: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated VasculitisUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan
This study looks at a new medicine called iptacopan for adults with a rare blood condition called PNH. It checks if switching to iptacopan is safe and works well for patients who are already feeling better on other treatments.
For: Paroxysmal Nocturnal Hemoglobinuria (PNH)Spain · Germany · France